Shahin M, El-Diasty AM, Mabed M. Anticardiolipin antibodies in proliferative diabetic retinopathy: An additional risk factor.
Saudi J Ophthalmol 2009;
23:165-9. [PMID:
23960854 PMCID:
PMC3729519 DOI:
10.1016/j.sjopt.2009.06.001]
[Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2009] [Accepted: 06/02/2009] [Indexed: 11/19/2022] Open
Abstract
PURPOSE
To report the prevalence of anticardiolipin antibodies in patients with proliferative diabetic retinopathy (PDR) having high-risk criteria (HRC).
METHODS
Diabetic patients having PDR with HRC and diabetics free of retinopathy were compared for the presence of anticardiolipin antibodies.
RESULTS
Among the 34 patients, 6 (17.7%) of diabetics having PDR with HRC were positive for anticardiolipin antibodies. There was no significant association of aCL antibodies with sex or type of diabetes. Using Pearson's correlation test, no significant associations of aCL antibodies with duration of diabetes or age of patients were found. All patients who were positive for anticardiolipin antibodies had PDR with HRC. The difference was statistically significant.
CONCLUSION
Presence of anticardiolipin antibodies may represent an additional risk factor for PDR.
Collapse